The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
复制标题
非酒精性脂肪性肝病的诊断和管理：美国肝病研究协会的实践指南
DOI：
10.1002/hep.29367
复制
发表时间：
2018-01-01
期刊：
影响因子：
13.5
通讯作者：
Sanyal, Arun J.
中科院分区：
文献类型：
--
作者：
Chalasani, Naga;Younossi, Zobair;Sanyal, Arun J.
缩略语：AASLD，美国肝病研究协会; ACG，美国胃肠病学会; AIH，自身免疫性肝炎; ALT，丙氨酸氨基转移酶; APRI，AST与血小板比率指数; AST，天冬氨酸氨基转移酶; AUROC，受试者工作曲线下面积; BMI，体重指数; CI，置信区间; CLD，慢性肝病; CT，计算机断层扫描; CVD，心血管疾病; ELF，增强型肝纤维化; FDA，美国食品药品监督管理局; FIB-4，纤维化-4指数; FLD，脂肪肝疾病; GFR，肾小球滤过率; GLP-1，胰高血糖素样肽-1; HCC，肝细胞癌; HCV，丙型肝炎病毒; HDL，高密度脂蛋白; HF，肝纤维化; HS，肝脂肪变性; ICD-10，国际疾病分类，第十版; IR，胰岛素抵抗; LDL，低密度脂蛋白; LT，肝移植; MET，代谢当量; MetS，MetS，代谢综合征; MR，磁共振; MRE，MR弹性成像; MRI，磁共振成像; NAFL，非酒精性脂肪肝; NAFLD，非酒精性脂肪肝; NAS，NAFLD活动性评分; NASH，非酒精性脂肪肝; NASH CRN，NASH临床研究网络; NFS，NAFLD纤维化评分; NIAAA，国家酒精滥用和酒精中毒研究所; OCA，奥贝胆酸; PNPLA-3，含马铃薯糖样磷脂酶结构域蛋白3; PPAR，过氧化物酶体增殖物激活受体γ; RCT，随机对照试验; SAF，脂肪变性活动性纤维化; SH，脂肪性肝炎; T2 DM，2型糖尿病; TE，一过性弹性成像; TG，甘油三酯; TONIC，治疗儿童非酒精性脂肪肝; UDCA，熊去氧胆酸; ULN，正常值上限; VCTE，振动控制的一过性弹性成像; WD，威尔逊病。
Abbreviations: AASLD, American Association for the Study of Liver Diseases; ACG, American College of Gastroenterology; AIH, autoimmune hepatitis; ALT, alanine aminotransferase; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; AUROC, area under the receiver operating curve; BMI, body mass index; CI, confidence interval; CLD, chronic liver disease; CT, computed tomography; CVD, cardiovascular disease; ELF, Enhanced Liver Fibrosis; FDA, US Food and Drug Administration; FIB-4, fibrosis-4 index; FLD, fatty liver disease; GFR, glomerular filtration rate; GLP-1, glucagon-like peptide-1; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HDL, high-density lipoprotein; HF, hepatic fibrosis; HS, hepatic steatosis; ICD-10, International Classification of Diseases, Tenth Revision; IR, insulin resistance; LDL, low-density lipoprotein; LT, liver transplantation; METs, metabolic equivalents; MetS, MetS, metabolic syndrome; MR, magnetic resonance; MRE, MR elastography; MRI, magnetic resonance imaging; NAFL, nonalcoholic fatty liver; NAFLD, nonalcoholic fatty liver disease; NAS, NAFLD activity score; NASH, nonalcoholic fatty liver disease; NASH CRN, NASH Clinical Research Network; NFS, NAFLD fibrosis score; NIAAA, National Institute on Alcohol Abuse and Alcoholism; OCA, obeticholic acid; PNPLA-3, patatin-like phospholipase domain-containing protein 3; PPAR, peroxisome proliferator-activated receptor gamma; RCT, randomized controlled trial; SAF, Steatosis Activity Fibrosis; SH, steatohepatitis; T2DM, type 2 diabetes mellitus; TE, transient elastography; TG, triglyceride; TONIC, treatment of nonalcoholic fatty liver disease in children; UDCA, ursodeoxycholic acid; ULN, upper limit of normal; VCTE, vibration controlled transient elastography; WD, Wilson’s disease.